ORIGINAL RESEARCH article

Front. Public Health

Sec. Health Economics

Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1538789

A Cost Analysis of Reductions in Work Productivity for MG Patients and their Caregivers by Symptom Severity

Provisionally accepted
Sarah  DewildeSarah Dewilde1*Cynthia  QiCynthia Qi2Femke  De RuyckFemke De Ruyck3Sandra  PaciSandra Paci3Lucas  Van de VeireLucas Van de Veire1Alison  GriffithsAlison Griffiths1Gil  WolfeGil Wolfe4Renato  MantegazzaRenato Mantegazza5Glenn  PhillipsGlenn Phillips2
  • 1Services in Health Economics, Brussels, Belgium
  • 2Argenx US Inc., Boston, Massachusetts, United States
  • 3argenx BVBA, Zwijnaarde, Belgium
  • 4Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Baffalo, New York, United States
  • 5IRCCS Carlo Besta Neurological Institute Foundation, Milan, Lombardy, Italy

The final, formatted version of the article will be published soon.

Myasthenia Gravis (MG) is a debilitating autoimmune disorder associated with fatigue and weakness in the ocular, respiratory, bulbar and limb muscles. This study evaluates productivity losses for MG patients and their caregivers by MG symptom severity.In the multinational MyRealWorld-MG study, 1049 MG patients and caregivers reported on work productivity (sick leave, reduced working hours, early retirement). Productivity losses were calculated using the average wage per hour. A UK perspective was adopted for the whole sample, and country-specific analyses were conducted for Italy, Spain and the US. The MG-Activities of Daily Living (MG-ADL) score was used to estimate the association between symptom severity and productivity losses, with patients categorized as having mild (0-4), moderate (5-9), or severe (>=10) symptoms.In the MyRealWorld-MG study, 36.5% MG patients reported taking sick leave within the last month and 11.4% reported stopping work (or retiring early) due to MG. Furthermore, 36.0% required caregiver support with 14.6% of caregivers reducing working hours and 13.4% stopping work. Mean productivity losses were £16,630/year for patients and caregivers combined, largely attributable to patient productivity losses (£13,891). Patients with severe MG incurred 3.8 times more productivity losses compared to patients with mild disease. Productivity loss estimates varied between Italy, Spain and the US.The impact of MG on patients' and caregivers' work productivity leads many of them to reduce work hours or retire early, resulting in significant productivity losses. The magnitude of these productivity losses is correlated with symptom severity and varies by country.

Keywords: ADAPT, Caregivers, Costs, efgartigimod, GMG, Generalized Myasthenia Gravis, MyRealWorld-MG, productivity losses

Received: 03 Dec 2024; Accepted: 03 Mar 2025.

Copyright: © 2025 Dewilde, Qi, De Ruyck, Paci, Van de Veire, Griffiths, Wolfe, Mantegazza and Phillips. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Sarah Dewilde, Services in Health Economics, Brussels, Belgium

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.